- Home
- MGTX vs PSNL Comparison
MGTX vs PSNL Comparison
Compare MGTX & PSNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGTX
- PSNL
- Stock Information
- Founded
- MGTX 2015
- PSNL 2011
- Country
- MGTX United States
- PSNL United States
- Employees
- MGTX N/A
- PSNL N/A
- Industry
- MGTX Biotechnology: Biological Products (No Diagnostic Substances)
- PSNL Medical Specialities
- Sector
- MGTX Health Care
- PSNL Health Care
- Exchange
- MGTX Nasdaq
- PSNL Nasdaq
- Market Cap
- MGTX 670.2M
- PSNL 484.0M
- IPO Year
- MGTX N/A
- PSNL 2019
- Fundamental
- Price
- MGTX $7.29
- PSNL $4.89
- Analyst Decision
- MGTX Strong Buy
- PSNL Strong Buy
- Analyst Count
- MGTX 2
- PSNL 4
- Target Price
- MGTX $24.00
- PSNL $8.13
- AVG Volume (30 Days)
- MGTX 321.7K
- PSNL 1.1M
- Earning Date
- MGTX 08-14-2025
- PSNL 08-05-2025
- Dividend Yield
- MGTX N/A
- PSNL N/A
- EPS Growth
- MGTX N/A
- PSNL N/A
- EPS
- MGTX N/A
- PSNL N/A
- Revenue
- MGTX $37,917,000.00
- PSNL $80,317,000.00
- Revenue This Year
- MGTX $145.67
- PSNL N/A
- Revenue Next Year
- MGTX $167.61
- PSNL $29.83
- P/E Ratio
- MGTX N/A
- PSNL N/A
- Revenue Growth
- MGTX 366.84
- PSNL 0.36
- 52 Week Low
- MGTX $3.85
- PSNL $2.83
- 52 Week High
- MGTX $8.98
- PSNL $7.79
- Technical
- Relative Strength Index (RSI)
- MGTX 41.87
- PSNL 45.83
- Support Level
- MGTX $7.34
- PSNL $4.44
- Resistance Level
- MGTX $7.75
- PSNL $4.93
- Average True Range (ATR)
- MGTX 0.40
- PSNL 0.26
- MACD
- MGTX -0.07
- PSNL 0.07
- Stochastic Oscillator
- MGTX 7.78
- PSNL 76.27
About MGTX MeiraGTx Holdings plc
MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.
About PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.